-
FDA approves Roche Amvetin and chemotherapy for treatment after initial surgical removal in women with advanced ovarian cancer
Time of Update: 2020-06-11
recently, the U.S Food and Drug ( FDA () approved Roche's Avastin (generic name: bevacizumab, bevamono) and chemotherapy (caplatinum y sequoia) after the combination of treatment to continue the
-
FDA approves joint development of antisense oligonucleotide drug Tegsedi (inotersen) to go on the market
Time of Update: 2020-06-11
hATTR is a deadly performing genetic disease caused by abnormal folding of transthyroxineprotein (TTR) in the patient, which causes amyloid TTR to be deposited in various tissues and organs of the b
-
FDA accepts applications for license seeking license for supplementary biologics from Peridome's Squibb Opdivo and low-dose Yervoy
Time of Update: 2020-06-11
recently, the (BMS) of The of Periasi announced that the U.S FDA (which has accepted supplemental biologic license applications (s) for Opdivo (nivolumab) and low-dose Yervoy (ierumiumpilab), an
-
The State Drug Administration approves the application for registration of the import of the Ikuju single anti-injection fluid
Time of Update: 2020-06-11
-in-the- hemoglobineuria (PNH) is an acquired hematopoietic stem cell clone disease of endogenous tonic inhibitors on the surface of blood cells; PNH and aHUS are among the rare diseases in the wor
-
The State Drug Administration approves Sanofio Batiere ® (Trifluoroamine tablet) to be listed in China
Time of Update: 2020-06-11
Sanofi China announced that the National Medicines (the Supervisory Authority has recently approved the ® of Aubameyang (Trifluoramine tablets) to be available in China for the treatment of recurr
-
Novartis announces results of clinical study PIONEER-HF for heart failure drug Entresto milestone
Time of Update: 2020-06-11
recently, Swiss Pharmaceuticals announced the results of a landmark clinical study of PIONEER-HF for heart failure drug (sacubitril/valsartan) about Entresto is a dual-acting angiotensin recep
-
Cutting-edge bio-new drug Ekonin ® (injecting With Abervet) gets CFDA approval for listing
Time of Update: 2020-06-11
AIDS is a major infectious disease in the field of public health, mainly through sexual transmission The number of infections in our country is still increasing, and the treatment of AIDS drugs (t
-
Johnson and Johnson's new anti-rheumatic biologic, The ® (Golimu mono-anti-injection) is available in China
Time of Update: 2020-06-11
recently, Johnson and Johnson Company (subsidiary Xi'an Yangsen Pharmaceutical co., Ltd.) announced that the company's monthly subcutaneous injection of new anti-rheumatic biological agent Simponi
-
Goliath has submitted to the State Drug Administration an application for the listing of the original oral hepatitis C cure program
Time of Update: 2020-06-11
recently, Goli announced that the Company's (to the State Medicines (the Supervisory Authority submitted China's first original research full oral hepatitis C treatment program to the market app
-
FDA approves XERAVA ™ for treatment of complex intraabdominal infections
Time of Update: 2020-06-11
intra-abdominal infection (IAI) is a common problem in the clinic, including a variety of disease processes Depending on the degree of infection, IAI is classified as simplicity or complexity Due to
-
Ion Channel Innovations (ICI) is licensed for global development and promotion by hMaxi-K
Time of Update: 2020-06-11
OAB is considered a smooth muscle disease of the genitourinary system, and by regulating smooth muscle tone, the relaxation of high-strained organs can serve therapeutic purposes OAB, characterized
-
FDA has accepted applications for new supplementary drugs from Incyte's Jakafi ® (Ruxolitinib) to treat acute transplant anti-host disease
Time of Update: 2020-06-11
recently, Incyte (announced that the FDA (Ruxo®litinib) has been accepted for the treatment of the acute graft anti-host disease (GVHD) of corticosteroids under-responsive and given priority re
-
Green leaf pharmaceutical new drug Palione re-release mixed suspension muscle injection (LY03010) has been approved by the FDA
Time of Update: 2020-06-11
recently, Greenleaf Pharmaceuticals (the Group announced that its independently developed new drug (LY03010) for the treatment of schizophrenia and schizophrenic emotional disorders (LY03010) ha
-
Astellas new drug roxadustat 3 placebo-controlled trial ALPS reaches major endpoint
Time of Update: 2020-06-11
CKD (also known as chronic renal insufficiency or chronic renal failure) is a disease in which renal function occurs with intractable decline over a period of months or years recently, Astellas Pha
-
Aishi achieved positive top-line results in phase 3 trials on the treatment of sleep-wake disorders in the study drug lemborexant
Time of Update: 2020-06-11
recently, Eisai and Purdue Pharma announced that their sleep-wake cycle swashes drug (in the phase 3 trial (2) for the treatment of sleep-wake disorders about the small molecular compound lembo
-
FDA approves fremanezumab-vfrm as a preventive treatment for migraines in adults
Time of Update: 2020-06-11
migraine is a common chronic neurovascular disease, characterized by recurrent seizures, one-sided or double-sided throbbing severe headache and mostly occurs in the side of the head, can be combine
-
Baxter pre-configured potassium chloride sodium chloride injection stoic sodium chloride injection approved by China's State Drug Administration officially listed
Time of Update: 2020-06-11
according to the relevant literature and reports, about 2.5 million people in China are by drug or drugs each year (adverse reactions prolong the length of hospitalization, and about 192,000 peopl
-
Gene Tek psychotherapy Tecentriq and chemotherapy in combination with the treatment of small cell lung cancer, their survival period reached the main clinical endpoint
Time of Update: 2020-06-11
recent days, Roche Group's Genentech company said that the company's immunotherapy Tecentriq and chemotherapy, in the treatment of small cell lung cancer, total survival (OS) and non-progressive s
-
China's State Drug Administration Accepts PD-1 Telli-Zhu-Dan-Ri-Dan-Ri-Dan-Ri-Mono-Resistance Application
Time of Update: 2020-06-11
late last month, Burlinger Ingeheim partner Baiji Shenzhou (NMPA) of China's National Medicines Administration (NMPA) has accepted its PD-1 Tilreju-Ju-Ri-Ju-Ri-Ri-Dan-Ri-Ri-Ri-Dana-ri applicatio
-
FDA grants praliciguat (IW-1973) fast-track status for heart failure reserved for blood-borne scores
Time of Update: 2020-06-11
recently, Ironwood Pharmaceuticals (Inc.) (the FDA ) has granted praliciguat (IW-1973) fast-track status for the treatment of heart failure (HFpEF) retained by the blood-borne fraction pralici
